Director buying at Profound Medical (T:PRN)

Arthur Lee Rosenthal, a Director, acquired 10,800 Common Shares on a direct ownership basis at prices ranging from $8.928USD to $9.483USD between May 31st, 2022 and June 2nd, 2022. This represents a $123,799 investment into the company's shares and an account share holdings change of greater than 100%.

Profound Medical is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Profound Medical Corp. is a Canada-based commercial-stage medical device company. The Company is focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare systems existing imaging infrastructure. The Company is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. The Company is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Profound Medical Corp. (PRN) has a high amount of executive buying compared to its small-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $123,799.